117 related articles for article (PubMed ID: 36417841)
1. Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Thelen H; Dilworth TJ; Mercier RC
Chemotherapy; 2022; 67(4):261-268. PubMed ID: 36417841
[TBL] [Abstract][Full Text] [Related]
2. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
[No Abstract] [Full Text] [Related]
3. Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.
Al-Tamimi M; Albalawi H; Shalabi M; Abu-Raideh J; Khasawneh AI; Alhaj F
Ann Clin Microbiol Antimicrob; 2022 May; 21(1):20. PubMed ID: 35599329
[TBL] [Abstract][Full Text] [Related]
4. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
6. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
8. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
[TBL] [Abstract][Full Text] [Related]
9. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
[TBL] [Abstract][Full Text] [Related]
10. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
11.
Gupta A; Malik S; Kaminski M; Landman D; Quale JM
Microb Drug Resist; 2022 Apr; 28(4):419-424. PubMed ID: 35451880
[TBL] [Abstract][Full Text] [Related]
12. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
14. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
[TBL] [Abstract][Full Text] [Related]
15. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
[TBL] [Abstract][Full Text] [Related]
16. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
17. Synergistic
Ract P; Compain F; Robin F; Decre D; Gallah S; Podglajen I
J Med Microbiol; 2019 Sep; 68(9):1292-1298. PubMed ID: 31361213
[No Abstract] [Full Text] [Related]
18. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
Marković T; Jeinić L; Smitran A; Petković M
Srp Arh Celok Lek; 2013; 141(11-12):775-9. PubMed ID: 24502096
[TBL] [Abstract][Full Text] [Related]
19. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
Meier S; Weber R; Zbinden R; Ruef C; Hasse B
Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
[TBL] [Abstract][Full Text] [Related]
20. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
